CD74–ROS1 L2026M mutant enhances autophagy through the MEK / ERK pathway to promote invasion, metastasis and crizotinib resistance in non‐small cell lung cancer cells
The FEBS Journal · 2024
DOI: 10.1111/febs.17032 ↗At a glance
Journal article in The FEBS Journal, 2024. Written by Xiaobo Xu and 6 co-authors. Institution: Department of Pharmacology, Shenyang Pharmaceutical University, China. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Cited 12 times so far (Crossref); 40 references. Funded by: National Natural Science Foundation of China, Innovative Talents Support Plan of Colleges and Universities in Liaoning Province.
Abstract (original language)
The treatment of non‐small cell lung cancer (NSCLC) patients harboring a proto‐oncogene tyrosine‐protein kinase c‐ros oncogene 1 ( ROS1 ) fusion gene has greatly benefited from the use of crizotinib. However, drug resistance inevitably occurs after 1 year of treatment. Clinical studies have shown that patients with an L2026M mutation in the ROS1 kinase domain account for about 6% of the total number of crizotinib‐resistant cases, which is an important group that cannot be ignored. To explore the mechanism involved, we constructed the HLA class II histocompatibility antigen gamma chain ( CD74 )– ROS1 L2026M mutant gene by fusion polymerase chain reaction (PCR) and transfected it into H460 and A549 cells. We found that the invasion and metastasis abilities of drug‐resistant cells were increased. The results of monodansylcadaverine (MDC) staining, Acridine orange (AO) staining, and western blot indicated that the autophagy level of CD74 – ROS1 L2026M mutant NSCLC cells was increased compared with the CD74 – ROS1 group, and the inhibition of autophagy could reverse the increased invasion and metastasis abilities caused by the L2026M mutation. In addition, the L2026M mutation led to excessive activation of the MEK/ERK pathway, and MEK inhibitors could reduce the autophagy level, invasion, and metastasis abilities of cells; additionally, this process could be blocked by rapamycin, an activator of autophagy. Furthermore, crizotinib treatment activated expression of Src homology region 2 domain‐containing phosphatase‐2 (SHP2; also known as PTPN11) to upregulate the MEK/ERK pathway, and the combination of MEK inhibitors and crizotinib increased apoptosis compared with crizotinib alone. In conclusion, our results indicate that the MEK/ERK pathway mediates the induction of invasion, metastasis, and crizotinib resistance through autophagy caused by CD74 – ROS1 L2026M mutation in NSCLC cells, and targeting MEK could reverse these processes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacology, Shenyang Pharmaceutical University, China.
ORCID profiles: Daiying Zuo, Yingliang Wu
Funding
- National Natural Science Foundation of China
- Innovative Talents Support Plan of Colleges and Universities in Liaoning Province
Cite
APA
Xu, X., Li, Y., Xu, R., Meng, Y., Li, Z., Zuo, D., & Wu, Y. (2024). CD74–ROS1 L2026M mutant enhances autophagy through the MEK / ERK pathway to promote invasion, metastasis and crizotinib resistance in non‐small cell lung cancer cells. The FEBS Journal. https://doi.org/10.1111/febs.17032
Vancouver
Xu X, Li Y, Xu R, Meng Y, Li Z, Zuo D, et al. CD74–ROS1 L2026M mutant enhances autophagy through the MEK / ERK pathway to promote invasion, metastasis and crizotinib resistance in non‐small cell lung cancer cells. The FEBS Journal. 2024. doi:10.1111/febs.17032
BibTeX
@article{Xu2024,
author = {Xu, Xiaobo and Li, Ye and Xu, Rui and Meng, Yuting and Li, Zengqiang and Zuo, Daiying and Wu, Yingliang},
title = {CD74–ROS1 L2026M mutant enhances autophagy through the MEK / ERK pathway to promote invasion, metastasis and crizotinib resistance in non‐small cell lung cancer cells},
journal = {The FEBS Journal},
year = {2024},
doi = {10.1111/febs.17032}
}
EUVIMED